Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases

Table 2 Single factor analysis of prognosis of the patients

Variable	n	Recurrent-free survival (%)		χ2	P value
		1 yr	3 yr
Gender				0.977	0.323
Male	61	91.4	55.9
Female	26	78.3	46.5
Age (yr)				0.509	0.475
≤ 60	50	82.7	49.6
> 60	37	94.2	57.4
Primary tumor size (cm)				0.006	0.937
≤ 5	66	87.1	56.2
> 5	21	89.5	46.4
Primary tumor site				5.365	0.068
Right colon	22	85.2	38.8
Left colon	37	83.2	47.3
Rectum	28	96.0	75.1
Differentiation				9.228	0.010
High	19	83.9	77.9
Moderate	50	93.2	55.4
Low	18	76.5	29.4
Pathological type				0.000	0.987
Non–MUC	75	88.4	51.2
MUC	12	83.3	64.3
CEA (ng/mL)				5.636	0.018
≤ 15	58	92.3	65.2
> 15	29	85.8	20.2
CA199 (U/mL)				0.029	0.866
≤ 37	60	92.3	55.0
> 37	27	85.5	52.2
LMN				0.385	0.535
No	39	91.2	55.3
Yes	48	83.2	51.3
CLM distribution				1.036	0.596
Right lobe	37	82.5	53.9
Left lobe	11	90.9	56.6
Both lobes	39	91.6	52.7
CLM number				4.152	0.042
≤ 4	50	90.7	59.6
> 4	37	91.4	29.1
Maximum CLM diameter				10.732	0.001
≤ 5 cm	65	93.2	61.4
> 5 cm	22	85.2	18.7
CLM treatments				8.158	0.043
Drug	13	90.9	51.9
Ablation	23	72.5	37.5
Intervention	15	92.3	34.6
Surgical resection	36	96.8	61.9
Proximity to great vessels				4.412	0.036
No	69	90.5	59.6
Yes	18	77.4	36.1
Postoperative chemotherapy time				0.367	0.545
≤ 6 mo	72	79.4	42.8
> 6 mo	15	89.5	56.3

MUC: Mucinous colorectal adenocarcinomas; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; LMN: Lymph node metastases; CLM: Colorectal liver metastases.